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AbstrACt
Introduction Fatigue is the second most common 
symptom in patients with chronic obstructive pulmonary 
disease (COPD). Despite its high prevalence, fatigue is 
often ignored in daily practice. For this reason, little is 
known about the underlying determinants of fatigue 
in patients with COPD. The primary objectives of this 
study are to chart the course of fatigue in patients with 
COPD, to identify the physical, systemic, psychological 
and behavioural factors that precipitate and perpetuate 
fatigue in patients with COPD, to evaluate the impact of 
exacerbation-related hospitalisations on fatigue and to 
better understand the association between fatigue and 
2-year all-cause hospitalisation and mortality in patients 
with COPD. The secondary aim is to identify diurnal 
differences in fatigue by using ecological momentary 
assessment (EMA). This manuscript describes the 
protocol of the FAntasTIGUE study and gives an overview 
of the possible strengths, weaknesses and clinical 
implications.
Methods and analysis A 2-year longitudinal, 
observational study, enrolling 400 patients with clinically 
stable COPD has been designed. Fatigue, the primary 
outcome, will be measured by the subjective fatigue 
subscale of the Checklist Individual Strength (CIS-Fatigue). 
The secondary outcome is the day-to-day/diurnal fatigue, 
registered in a subsample (n=60) by EMA. CIS-Fatigue 
and EMA will be evaluated at baseline, and at 4, 8 and 
12 months. The precipitating and perpetuating factors of 
fatigue (physical, psychological, behavioural and systemic) 
will be assessed at baseline and at 12 months. Additional 
assessments will be conducted following hospitalisation 
due to an exacerbation of COPD that occurs between 
baseline and 12 months. Finally, at 18 and 24 months the 
participants will be followed up on their fatigue, number 
of exacerbations, exacerbation-related hospitalisation and 
survival.
Ethics and dissemination This protocol was approved 
by the Medical research Ethics Committees United, 
Nieuwegein, the Netherlands (NL60484.100.17).
trial registration number NTR6933; Pre-results.
IntroduCtIon 
Fatigue, the subjective feeling of tiredness 
or exhaustion, is next to dyspnoea, the 
most common and distressing symptom in 
patients with chronic obstructive pulmonary 
disease (COPD).1 It affects the ability to 
perform activities of daily living and impacts 
the patient’s quality of life.2 3 Among 
patients with stable moderate to severe 
COPD, around 50% experiences mild to 
severe fatigue,4 which is significantly higher 
compared with elderly, non-COPD subjects.5 
Nevertheless, despite its high prevalence and 
significant negative health consequences, 
fatigue remains often undiagnosed and, in 
turn, untreated.6 This might be due to the 
under-representation of fatigue questions 
in commonly used health status assessment 
tools.7 8 Moreover, relatively few studies 
have focused on the symptom fatigue and, 
strengths and limitations of this study
 ► This study is a large, longitudinal, multicentre study 
evaluating a wide range of possible precipitating 
and perpetuating factors of mild to severe fatigue in 
patients with chronic obstructive pulmonary disease 
(COPD).
 ► The ecological momentary assessment data will give 
us more insight in the diurnal variations of fatigue.
 ► The longitudinal design enables to examine the 
association between fatigue, exacerbation-related 
hospitalisations and mortality and allows us to in-
vestigate whether the associations between fatigue 
and the explaining factors are temporary or fluctuate 
over time.
 ► The perpetuating and precipitating factors have 
been carefully selected; it is—however—possible 
that there are other factors that contribute to fatigue 
in COPD that will be missed.
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therefore, little is known about the precipitating and 
perpetuating factors of mild to severe fatigue in patients 
with COPD. Consequently, specific interventions aimed 
at reducing COPD-related fatigue are lacking. A better 
insight into the underlying determinants will provide 
guidance for the development of personalised inter-
ventions for this important yet disregarded symptom in 
patients with COPD.9 
Multiple precipitating factors are expected to play a 
role in the cause of COPD-related fatigue.9 It has been 
suggested that COPD-specific features are associated 
with fatigue, since the prevalence of fatigue is higher 
in patients with COPD compared with elderly control 
subjects.5 However, evidence suggests that fatigue is not 
related to the degree of airflow limitation.4 This indi-
cates that the degree of airflow limitation may not be 
the primary underlying cause of mild to severe fatigue in 
patients with COPD. On the other hand, a COPD exacer-
bation precipitates mild to severe fatigue.5 10 However, the 
size of the impact of an exacerbation-related hospitalisa-
tion on fatigue remains to be clarified.
Next to precipitating factors, various physical, systemic, 
psychological and behavioural factors are assumed to 
perpetuate mild to severe fatigue in patients with COPD. 
Generally, studies report significant, weak to moderate 
associations between fatigue and health status, exercise 
performance, physical activity, functional impairments, 
sleep quality, symptoms of anxiety or depression and 
mood status.2 5 11–15 Moreover, research indicates that 
COPD is associated with low-grade systemic inflamma-
tion.16 Nonetheless, whether and to what extent low-grade 
systemic inflammation is related to fatigue needs to be 
further explored.
Thus, fatigue in COPD is a complex symptom, due to 
a combination of precipitating and perpetuating factors. 
To date, the above-mentioned factors have rarely been 
assessed comprehensively in one study in patients with 
COPD.17 Moreover, the role of sleep apnoea, comor-
bidities, medication and exacerbation-related hospital-
isations are unknown. Therefore, we have designed a 
longitudinal, observational study, which evaluates a wide 
range of possible underlying factors of mild to severe 
fatigue in patients with COPD. This manuscript describes 
the protocol of the FAntasTIGUE study and gives an over-
view of its possible strengths, weaknesses and clinical 
implications.
objectives of this study
The primary objectives of the FAntasTIGUE study are:
1. To chart the course of fatigue in patients with COPD.
2. To identify physical, systemic, psychological and be-
havioural factors that precipitate and/or perpetuate 
fatigue in patients with COPD.
3. To identify the impact of exacerbation-related hospi-
talisations on fatigue and its perpetuating factors.
4. To better understand the association between base-
line fatigue and 2-year all-cause hospitalisation and 
mortality in patients with COPD.
The secondary objective of this study is:
1. To identify diurnal differences in fatigue by augment-
ing traditional questionnaire data with ecological mo-
mentary assessment (EMA).
MEthods
The FAntasTIGUE study is a collaboration between CIRO 
(Horn, The Netherlands), Radboud University Medical 
Centre (Nijmegen, The Netherlands), Academic Medical 
Centre (Amsterdam, The Netherlands), Maastricht 
University Medical Centre (Maastricht, The Nether-
lands) and Hasselt University (Diepenbeek, Belgium). 
The consortium consists of members from various disci-
plines and backgrounds (eg, chest physicians, clinical 
psychologists, an elderly care specialist, a cardiologist, a 
general practitioner and researchers), to ensure neces-
sary know-how to enable the successful completion of 
the project. Moreover, a patient advisory board is closely 
involved to advise and monitor the FAntasTIGUE project, 
by providing valuable insight from the patient perspective.
Patient and public involvement
Based on the input of patients with chronic lung disease, 
fatigue was prioritised as a research topic during the Neth-
erlands Respiratory Society meeting (www. nation aalp rogr 
amma long onde rzoe k. nl).18 As stated, patient representa-
tives are full members of the FAntasTIGUE consortium, 
and have an active role in the decision process. The 
patient advisory board has been involved in setting up the 
proposal, in reviewing the study design before submission 
to the ethical committee and in discussing the schedules 
of assessment. After completion of the study, the patient 
advisory board will also be asked to be involved in the 
development of post-trial communication.
study design
A 2-year longitudinal, observational study, enrolling 
patients with clinically stable COPD has been designed 
(figure 1). The assessments at baseline, 12 months and 
during the first 4 days of a possible exacerbation-related 
hospitalisation will be performed in a hospital setting. 
The remaining measurements at 4, 8, 18 and 24 months 
will take place at the patients’ homes.
The primary outcome fatigue severity will be assessed 
with a questionnaire at baseline, and at 4, 8, 12, 18 and 
24 months, as well as during exacerbation-related hospi-
talisations and 2 weeks after discharge. The secondary 
outcome, day-to-day/diurnal variation in fatigue, will be 
registered using EMA in a subsample (n=60) at baseline, 
and at 4, 8 and 12 months. Selection is based on conve-
nient sampling, a ‘first-come, first-serve’ approach. The 
precipitating and perpetuating factors of mild to severe 
fatigue in patients with COPD (physical, psychological, 
behavioural and systemic factors) will be assessed at base-
line and at 12 months. Also, when patients are admitted 
to the hospital between baseline and 12 months due to 
an exacerbation of COPD, some tests will be repeated 
during the first 4 days of hospitalisation and 2 weeks after 
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discharge. At last, at 18 and 24 months the participants 
will be followed up on their fatigue, number of exacerba-
tions, exacerbation-related hospitalisations and survival.
Eligibility criteria
To be eligible, a subject must meet the following criteria:
1. A diagnosis of COPD according to the Global Strategy 
for the Diagnosis, Management and Prevention of 
COPD (GOLD, grade 1A–4D), with a postbronchodi-
lator forced expiratory volume in 1 s (FEV1) to forced 
vital capacity (FVC) ratio, FEV1/FVC <0.7.
19
2. No exacerbation-related hospitalisation less than 4 
weeks preceding enrolment.
3. No use of oral corticosteroids and/or antibiotics less 
than 4 weeks preceding enrolment.
4. Provided written informed consent.
Patients lacking a sufficient understanding of the 
Dutch language and/or participating in concurrent 
intervention studies will be excluded. There are no age or 
smoking status restrictions, as well as no exclusion based 
on comorbidities or the use of long-term oxygen therapy.
Extra eligibility criteria for the EMA substudy are as 
follows:
1. Access to the internet at home (Wi-Fi).
2. Able to operate a smartphone/iPod.
recruitment
Participants will be recruited at the outpatient clinics of 
the Department of Respiratory Medicine in Maastricht 
and the Department of Pulmonary Diseases in Nijmegen, 
and from the registration Network of Family Practices 
(RNH) of Maastricht University.20 Eligible patients from 
the outpatient clinics will be informed about the research 
by their physician during their pulmonary consulta-
tion and are asked if the investigator may contact them 
to provide detailed information. Patients recruited via 
the RNH network will receive a letter on behalf of their 
general practitioner introducing the research project. In 
case the patient agrees to participate, an appointment 
for the baseline assessment at the hospital will be made. 
Written informed consent will be obtained at the begin-
ning of this visit.
outCoMEs
Primary outcome
Fatigue severity will be measured by the subjective fatigue 
subscale of the Checklist Individual Strength (CIS-Fa-
tigue).21 The CIS-Fatigue consists of eight items scored 
on a seven-point Likert scale. The scores range from 8 
(normal fatigue) to 56 (most severe fatigue). A score of 
26 or lower indicates normal fatigue, scores between 27 
to 35 indicate mild fatigue and a score of 36 or higher 
indicates severe fatigue. The CIS-Fatigue is a standardised 
and validated questionnaire that has been used in healthy 
subjects,22–24 and among various patient populations 
including COPD.21 25–27 The CIS-Fatigue will be admin-
istered at baseline, and at 4, 8, 12, 18 and 24 months, as 
well as during exacerbation-related hospitalisations and 
2 weeks after discharge.
Figure 1 Timeline: measurements will be performed at baseline, and at months 4, 8 and 12. Additional measurements will be 
carried out when a non-elective, exacerbation-related hospitalisation occurs. Patients will be followed up at month 18 and 24.
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secondary outcome
Day-to-day/diurnal variations of fatigue will be measured 
in a subsample (n=60) with EMA.28 29 EMA involves 
repeated measurements of the participant’s behaviour 
and context in vivo and in real time. In the current study, 
the participants will be given an iPod for the duration of 
the study with the EMA application (www. psymate. eu) 
installed. The participants will be prompted to answer 
questions about their fatigue, context and surroundings, 
eight times per day at random moments between 7:30 
and 22:30 for five consecutive days at baseline, and at 4, 8 
and 12 months. Patients will be given instructions to carry 
the device with them at all times for five consecutive days. 
Furthermore, they will be requested to fill out the ques-
tions immediately after the alert and to keep a normal 
day/night routine.
Explanatory factors
Table 1 provides an overview of the precipitating and 
perpetuating factors of mild to severe fatigue that will be 
assessed at baseline, and at months 4, 8, 12, 18 and 24, as 
well as during non-elective, exacerbation-related hospital-
isations and 2 weeks after discharge.
Questionnaires will be completed via RadQuest in the 
home environment. RadQuest allows very simple online 
questionnaire completion. If, for any reason (eg, no PC 
or internet connection) it is not possible to fill out the 
questionnaires via RadQuest, the participant will receive 
a paper version. Regarding the systemic factors, we will 
collect blood at baseline to assess systemic high-sensi-
tivity C-reactive protein, interleukin-6 (IL-6), tumour 
necrosis factor-α (TNF-α), IL-1α, IL-1β, IL-1-RA, IL-10, 
fibrinogen, leukocytes, cortisol, haemoglobin, glucose, 
thyroid function, renal function (creatinine), sodium, 
potassium, calcium, magnesium, vitamin B12, vitamin 
25(OH)D3, liver function (aspartate aminotransferase 
and alanine aminotransferase), N-Terminal pro-Brain 
Natriuretic Peptide, blood sediment, antinuclear anti-
bodies and DNA.
sample size calculation
A total of 260 patients are needed to detect a medium to 
small effect size of 0.175 between factors (218 (2 groups 
with or without an exacerbation) or 264 (3 groups normal, 
mild or severe fatigue)) and a small effect within-between 
factors (222 (3 groups normal, mild or severe fatigue)), 
with a power of 90%, a significance level of 5% and an 
expected drop-out rate of 20%.30 Nevertheless, as a rather 
large number of possible perpetuating and precipitating 
factors will be evaluated, it is decided to augment the 
sample size to 400 inclusions.
For EMA, a sample of 60 patients with each 160 obser-
vations (5 days with eight measurements, collected over 
four time points) ensures that the EMA analyses are 
adequately powered to detect differences in fatigue, 
based on a power of 0.8 and two-tailed significance of 
0.05.31
data management and statistical analysis
Missing data of questionnaires will be minimised using 
RadQuest, since items cannot be skipped. In case of 
missing data for other variables, the likeliness of this being 
missing at random will be assessed. If missing data are 
random, we will use appropriate imputation methods.32
All statistical analyses will be performed using statistics 
software (SPSS V.25.0 for Windows). First, to characterise 
transitions over time in fatigue, we will use latent transi-
tion analysis.33 Second, to identify the factors that precip-
itate and/or perpetuate fatigue in patients with COPD, 
mixed model analyses will be applied for continuous 
outcomes measures and generalised estimating equations 
for dichotomous outcomes measures. Third, to study the 
impact of exacerbation-related hospitalisations on fatigue 
and its perpetuating factors we will use mixed model anal-
yses. Fourth, to better understand the extent to which 
baseline fatigue is related to 2-year all-cause hospitalisa-
tion and mortality, Cox proportional hazard models will 
be applied. At last, to identify whether there are diurnal 
differences in fatigue and what factors are associated with 
these variations, we will use hierarchical linear modelling 
as items are nested within moments and moments are 
nested within individuals. The responsiveness and sensi-
tivity of the fatigue questionnaire versus EMA data are 
compared with effect sizes (Cohen’s d) for the compo-
nent of observed change derived from model parame-
ters. A priori, a two-tailed p value of <0.05 is considered 
significant.
Ethics and dissemination
This study will be conducted according to the princi-
ples of the Declaration of Helsinki (64th WMA General 
Assembly, Fortaleza, Brazil, October 2013) and in accor-
dance with the Medical Research Involving Human 
Subject Act (WMO). The study was registered on www. 
trialregister. nl on 8 January 2018. The results will be 
submitted for publication in peer-reviewed journals and 
will be presented at (inter)national conferences.
dIsCussIon
The FAntasTIGUE study has been designed to identify 
the factors that perpetuate and/or precipitate mild to 
severe fatigue in patients with COPD. The novel findings 
will hopefully further guide the development of tailored 
interventions, which—in turn—will help to diminish 
the impact on daily life of this important yet ignored 
symptom.
strengths
A major strength of the FAntasTIGUE study is that a wide 
range of possible precipitating and perpetuating factors 
will be tested concurrently in one model of stable patients 
with COPD. Moreover, the FAntasTIGUE study also exam-
ines the impact of an exacerbation-related hospitalisation 
on fatigue. This way, we aim to identify relevant factors 
that explain variance in fatigue. Another strength of this 
 o
n
 16 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021745 on 10 April 2018. Downloaded from 
5Goërtz YMJ, et al. BMJ Open 2018;8:e021745. doi:10.1136/bmjopen-2018-021745
Open Access
Table 1 Overview outcome measurements
Number (n) 0 month 4 months 8 months 12 months 18 months 24 months
Exacerbation-
related 
hospitalisations*
Fatigue 
Subjective fatigue subscale of the 
Checklist Individual Strength (CIS-
Fatigue)21
400 • • • • • • •
Ecological momentary 
assessment28 29
60 • • • •
Sociodemographic factors 
Gender 400 •
Age 400 •
Social-economic status34 400 •
Marital status 400 • •
Survival status 400 • • • • • •
Physical factors 
Current medication 400 • •
Charlson Comorbidity Index35 400 • •
Symptoms checklist36 400 • •
Modified Medical Research Council 
(mMRC) dyspnoea scale37
400 • • • • •
Exacerbations last 4 or 6 months (as 
appropriate)
400 • • • • • •
All-cause hospitalisations 400 • • • • • •
Body mass index 400 • •
Waist circumference 400 • •
Bioelectrical impedance analyses38 400 • •
6 min Walk Test39 400 • •
Short Physical Performance 
Battery40
400 • •
Lower limb muscle function 
(MicroFet2 Wireless Hand-held 
Dynamometer)41
400 • •
Hand grip strength42 400 • •
Lung function (postbronchodilator 
spirometry, whole-body 
plethysmography, and transfer 
factor for carbon monoxide)
400 •
Peripheral arterial disease (Dopplex 
D900, Huntleigh Healthcare, Cardiff, 
UK)43 44
400 • •
Resting cardiac echocardiography 
(Maastricht only)
200 •
Resting ECG(Maastricht only) 200 •
Retinal microcirculation45 
(Maastricht only)
200 •
Polysomnography (Maastricht only) 50 •
Psychological factors 
Nijmegen Clinical Screening 
Instrument46
400 • •
COPD Assessment Test8 400 • • • • •
Euroqol-5d-5L47 400 • •
Hospital Anxiety Depression Scale48 400 • • • • •
Montreal Cognitive Assessment49 400 • •
Continued
 o
n
 16 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021745 on 10 April 2018. Downloaded from 
6 Goërtz YMJ, et al. BMJ Open 2018;8:e021745. doi:10.1136/bmjopen-2018-021745
Open Access 
study is the use of EMA to capture diurnal variations of 
fatigue in patients with COPD. In comparison with the 
usual web-based or paper-and-pencil questionnaires, 
data gathered via EMA are not subject to recall bias and 
provide us with a film of variations in the patient’s fatigue 
in their natural environment rather than a snapshot. To 
our knowledge, this is the first study that uses EMA to eval-
uate fatigue in a population of patients with COPD. The 
information about the diurnal variations of fatigue will 
further help us to tailor interventions for reducing fatigue 
in patients with COPD. Moreover, EMA provides us with 
contextual information of factors that could precipitate 
or perpetuate fatigue. A methodological strength of this 
study is the longitudinal design. It enables us to examine 
the association between fatigue, exacerbation-related 
hospitalisations and mortality. Moreover, it allows us to 
investigate if the associations between fatigue and the 
precipitating and perpetuating factors are temporarily 
or can change over time. And last, the structure of the 
FAntasTIGUE consortium, including a steering committee 
and a patient’s advisory board, allows us to improve the 
research capacity, to share (academic) resources, to 
disseminate study results and to speed up future research.
Limitations
The present study may encounter the following limita-
tions: first, despite the benefits of repeated measure-
ments in longitudinal studies, higher drop-out rates are 
expected as disease progresses. This attrition could result 
in a biased sample, which may compromise the study’s 
generalisability. To limit the loss to follow-up, we will 
minimise the burden as much as possible and keep close 
contact with the patients. The patient advisory board 
has been intimately involved in the design of the FAntas-
TIGUE project to balance patient burden and number of 
variables that needed to be assessed to identify the factors 
that perpetuate and/or precipitate mild to severe fatigue 
in patients with COPD. Second, the current study selec-
tion is based on convenience sampling. This may cause 
selection bias, since participants with a lack of motivation 
Number (n) 0 month 4 months 8 months 12 months 18 months 24 months
Exacerbation-
related 
hospitalisations*
Qualitative experience of fatigue 
(KWAMOE)50
400 • •
Acceptance of Disease and 
Impairments Questionnaire51
400 • •
Fatigue-related self-efficacy (Self-
Efficacy-5)52
400 • •
Jacobsen Fatigue Catastrophising 
Scale53
400 • •
Fear of Progression Questionnaire54 400 • •
Patient Activations Measure55 400 • •
Activity Cognitions Instrument (self-
developed questionnaire)
400 • •
Behavioural factors 
Smoking status 400 • •
Alcohol consumption 400 • •
Caffeine consumption 400 • •
Objectified physical activity 
(Actigraph GT9X Link, 3-axis activity 
monitor, sample frequency 30 Hz)56
400 • •
Pittsburgh Sleep Quality Index57 400 • •
Epworth Sleepiness Scale58 400 • •
Causal Attribution List59 400 • •
Sickness Impact Profile60 400 • •
Social Support List, Interactions and 
Discrepancies61
400 • •
Systemic factors 
Venous blood samples 400 •
*Non-elective hospitalisations due to an exacerbation of COPD may occur at any moment after the start of the study. Those which occur 
between baseline and 12 months will result in additional measurements. Those which may occur between 12 and 24 months will not result in 
additional measurement.
COPD, chronic obstructive pulmonary disease, mMRC, modified Medical Research Counsil
Table 1 Continued 
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and a higher disease burden are less likely to respond. We 
will try to prevent selection bias, by inviting all patients 
who are diagnosed with COPD either via their physician 
during consultation hour or via their own general practi-
tioner. Third, together with the steering committee and 
patient advisory board, the perpetuating and precipi-
tating factors that will be evaluated have been carefully 
selected. However, we still may miss other factors that 
potentially contribute to fatigue in COPD.
Clinical implications
The results of the FAntasTIGUE study will contribute to 
a better understanding of the physical, psychological, 
behavioural and systemic factors that precipitate and/or 
perpetuate fatigue in patients with COPD when studied 
concurrently. Furthermore, it will give us more insight in 
the diurnal variations of fatigue and the impact of exac-
erbations on fatigue. These findings will provide further 
guidance for the development of fatigue-reducing and 
coping interventions to improve the daily functioning of 
patients with COPD. This will be an important first step in 
the management of COPD-related fatigue.
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